

# Long non-coding RNA KCNQ1OT1 promotes nasopharyngeal carcinoma cell cisplatin resistance via the miR-454/USP47 axis

FENG YUAN<sup>1</sup>, ZHIPING LOU<sup>1</sup>, ZHIFENG ZHOU<sup>2</sup> and XIAOJUN YAN<sup>3</sup>

<sup>1</sup>Department of Otolaryngology, Zhuji Hospital Affiliated to Shaoxing College of Arts and Sciences;

<sup>2</sup>Department of Otolaryngology, Zhuji Central Hospital, Zhuji, Zhejiang 311800; <sup>3</sup>Department of Otorhinolaryngology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China

Received July 31, 2020; Accepted January 11, 2021

DOI: 10.3892/ijmm.2021.4887

**Abstract.** Long non-coding RNAs serve an essential role in drug resistance in various types of cancer, including lung, breast and bladder cancer. The present study aimed to investigate whether KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) was associated with cisplatin (DDP) resistance in nasopharyngeal carcinoma (NPC). KCNQ1OT1, microRNA (miR)-454 and ubiquitin specific peptidase 47 (USP47) expression levels were measured via reverse transcription-quantitative PCR. 5-8F/DDP and SUNE-1/DDP cell viability and chemosensitivity were assessed by performing Cell Counting Kit-8 assays. Colony forming and Transwell assays were conducted to assess the effect of the KCNQ1OT1/miR-454/USP47 axis on DDP resistance in NPC cells. The association between miR-454 and KCNQ1OT1 or USP47 was verified via bioinformatics analysis, dual-luciferase reporter assays and RIP assays. KCNQ1OT1 and USP47 expression levels were significantly upregulated, whereas miR-454 expression levels were significantly downregulated in DDP-resistant NPC cells compared with parental NPC cells. KCNQ1OT1 knockdown promoted chemosensitivity in DDP-resistant NPC cells (5-8F/DDP and SUNE-1/DDP), as indicated by significantly decreased cell proliferation, migration and invasion in the short hairpin RNA (sh)KCNQ1OT1 group compared with the sh-negative control (NC) group. Moreover, miR-454 was identified as a target of KCNQ1OT1. KCNQ1OT1 overexpression significantly reversed miR-454 overexpression-mediated effects on NPC

cell viability and DDP resistance. Furthermore, the results indicated that miR-454 directly targeted USP47. Compared with the shNC group, USP47 knockdown significantly suppressed NPC cell viability and DDP resistance, which was significantly reversed by co-transfection with miR-454 inhibitor. Furthermore, compared with the shNC group, KCNQ1OT1 knockdown significantly downregulated USP47 expression, which was significantly counteracted by miR-454 knockdown. Collectively, the results of the present study indicated that KCNQ1OT1 enhanced DDP resistance in NPC cells via the miR-454/USP47 axis, suggesting a potential therapeutic target for patients with DDP-resistant NPC.

## Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common types of head and neck tumor (1,2). The incidence of NPC varies significantly worldwide, but is primarily prevalent in East Africa, North Africa, East Asia and Southeast Asia (3). At present, platinum chemotherapy is a widely used treatment strategy for NPC, and cisplatin (DDP) is a common platinum compound that has been reported to be effective in the treatment of cancer (4). However, drug resistance often leads to the failure of NPC chemotherapy (5). Therefore, understanding the mechanism underlying DDP resistance in NPC might aid with improving the prognosis of patients with NPC.

Long non-coding RNAs (lncRNAs), a class of transcripts >200 nucleotides in length, lack protein-coding capacity (6) and serve as regulatory factors in multiple biological processes, including apoptosis, metabolism and cell proliferation (7,8). Increasing evidence has demonstrated that lncRNAs confer chemoresistance in various types of cancer, such as renal and hepatocellular cancer (9,10). Several lncRNAs serve a vital role in drug resistance of NPC. For instance, lncRNA MAGI2 antisense RNA 3 conferred DDP resistance in NPC cells via regulating the microRNA (miRNA/miR)-218-5p/glycerophosphodiester phosphodiesterase domain containing 5 axis (11). lncRNA nuclear paraspeckle assembly transcript 1 promoted DDP resistance in NPC cells via the let-7a-5p/remodeling and spacing factor 1 axis (12). Testis associated oncogenic lncRNA knockdown inhibited tumorigenicity and attenuated DDP resistance in NPC cells (13). However, the function of KCNQ1OT1 in mediating chemoresistance in NPC is not completely understood.

*Correspondence to:* Dr Zhifeng Zhou, Department of Otolaryngology, Zhuji Central Hospital, 98 Zhugong Road, Zhuji, Zhejiang 311800, P.R. China  
E-mail: zhouzhifeng37@163.com

Dr Xiaojun Yan, Department of Otorhinolaryngology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, 639 Zhizaoju Road, Shanghai 200011, P.R. China  
E-mail: yanxiaojun1974@163.com

**Key words:** KCNQ1 opposite strand/antisense transcript 1, microRNA-454, ubiquitin specific peptidase 47, nasopharyngeal carcinoma, cisplatin resistance

miRNAs, small non-coding RNAs that are 20-22 nucleotides in length, serve important roles in multiple cellular processes, including cell proliferation and survival, of human tumors (14). Previous studies have revealed that dysregulated miRNAs could mediate the sensitivity of NPC cells to DDP by targeting mRNAs. For example, miR-19b served an important role in inhibiting cancer progression and promoting NPC sensitivity to DDP via inhibiting KRAS (15). Furthermore, miR-205-5p facilitated cell proliferation and DDP resistance in NPC by repressing PTEN (16). miR-139 overexpression suppressed DDP-induced progression and enhanced apoptosis in NPC cells (17). Nevertheless, the mechanism underlying miR-139 in tumorigenesis and chemosensitivity in NPC is not completely understood.

The present study investigated the regulatory role of KCNQ1OT1 in DDP resistance of NPC, and the results of the present study might provide a novel therapeutic strategy for DDP-resistant NPC.

## Materials and methods

**Patients.** A total of 50 patients (31 male patients and 19 female patients; age range, 26-65 years; mean age, 46 years) with NPC (29 DDP-resistant and 21 DDP-sensitive) at Zhuji Central Hospital (Zhuji, China) were recruited between August 2017 and December 2019. The inclusion criteria were as follows: i) Diagnosed with NPC; and ii) had not received preoperative radiotherapy, chemotherapy or other adjuvant treatments. The exclusion criteria were as follows: i) Diagnosed with other diseases; and ii) failed to cooperate with researchers. All specimens were immediately frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ . The present study was approved by the Ethical Committee of Zhuji Central Hospital. Written consent was obtained from all patients prior to starting the study.

**Cell lines and culture.** NPC cell lines (5-8F and SUNE-1) were purchased from The Cell Bank of Type Culture Collection of The Chinese Academy of Sciences. 5-8F and SUNE-1 cells were cultured in RPMI-1640 (Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific). To establish DDP-resistant NPC cells (5-8F/DDP and SUNE-1/DDP), cells were treated with  $0.5\ \mu\text{g/ml}$  DDP (Qilu Pharmaceutical Co., Ltd.) at  $37^{\circ}\text{C}$  for 3 weeks and then exposed to gradually increasing concentrations of DDP (2, 4, 6 or  $8\ \mu\text{g/ml}$ ) every 3 weeks up to a final concentration of  $10\ \mu\text{g/ml}$  for a total 15 weeks. 5-8F/DDP and SUNE-1/DDP cells were cultured in RPMI-1640 supplemented with  $5\ \mu\text{g/ml}$  DDP and 10% FBS. All cells were cultured at  $37^{\circ}\text{C}$  with 5%  $\text{CO}_2$ .

**Cell transfection.** Short hairpin (sh)RNA targeting KCNQ1OT1 (shKCNQ1OT1;  $0.8\ \mu\text{g}$ ; 5'-GCAGAACCAUCG AUGGUGCGU-3'), shRNA targeting USP47 (shUSP47;  $0.8\ \mu\text{g}$ ; 5'-GCCUUUGCAGACUCUCAUUUA-3'), shRNA-negative control (NC; shNC;  $0.8\ \mu\text{g}$ ; scrambled; 5'-AGUGCUGCG CACGUGUCUCAU-3'), miR-454 mimics ( $100\ \text{nM}$ ; 5'-UAG UGCAAUAUUGC UUAUAGGGU-3'), NC mimics ( $100\ \text{nM}$ ; 5'-UUGUACUACACAAAAGUACUG-3'), miR-454 inhibitor ( $100\ \text{nM}$ ; 5'-ACCCUAUAAGCAAUAUUGCACUA-3') and NC inhibitor ( $100\ \text{nM}$ ; 5'-CAGUACUUUUGUGUAGUA

CAA-3') were purchased from Shanghai GenePharma Co., Ltd. To overexpress KCNQ1OT1 or USP47, the full-length KCNQ1OT1 sequence was inserted into the pcDNA3.1 vector (Shanghai GenePharma Co., Ltd.). 5-8F/DDP and SUNE-1/DDP cells ( $1 \times 10^5$ ) were transfected with shRNA, miR-mimics, miR-inhibitors, overexpression vectors and the corresponding NCs using Lipofectamine<sup>®</sup> 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at  $37^{\circ}\text{C}$ . At 48 h post-transfection, subsequent experiments were performed.

**Reverse transcription-quantitative PCR (RT-qPCR).** Total RNA was extracted from tissues and cells using TRIzol<sup>®</sup> reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio, Inc.) according to the manufacturer's protocol. Subsequently, qPCR was performed using SYBR<sup>®</sup> Premix Ex Taq<sup>™</sup> II (Takara Bio, Inc.) on the ABI 7500 real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used for qPCR: Initial denaturation at  $95^{\circ}\text{C}$  for 15 sec; 40 cycles of denaturation at  $94^{\circ}\text{C}$  for 30 sec, annealing at  $60^{\circ}\text{C}$  for 20 sec and extension at  $72^{\circ}\text{C}$  for 40 sec. The following primers were used for qPCR: KCNQ1OT1 forward, 5'-TTG GTAGGATTTTGTGAGG-3' and reverse, 5'-CAACCTCC CCTACTACC-3'; miR-454 forward, 5'-TAGTGCAAUATT GCTTAUAGGGT-3' and reverse, 5'-CCUAUAAGCAAUATT GCACTATT-3'; USP47 forward, 5'-GGCAGGACGCTCATT AGGT-3' and reverse, 5'-GCACAACATGATTCGAAGTCA A-3'; GAPDH forward, 5'-TCAAGGCTGAGAACGGGA AG-3' and reverse, 5'-TGGACTCCACGACGTACTCA-3'; and U6 forward, 5'-CTCGCTTCGGCAGCACATATACT-3' and reverse, 5'-CGCTTCACGAATTTGCGTGT-3'. miRNA and mRNA expression levels were quantified using the  $2^{-\Delta\Delta\text{Cq}}$  method (18) and normalized to the internal reference genes U6 and GAPDH, respectively.

**Colony forming assay.** Transfected 5-8F/DDP and SUNE-1/DDP cells were trypsinized and seeded ( $1 \times 10^3$  cells/well) into 6-well plates. Subsequently, cells were cultured in RPMI-1640 supplemented with 10% FBS for 2-3 weeks. Visible colonies were fixed in 4% paraformaldehyde for 10 min at room temperature and stained with 0.1% crystal violet for 10 min at room temperature (Sigma-Aldrich; Merck KGaA). Stained colonies ( $>30$  cells) were counted using a light microscope (magnification,  $\times 40$ ) and the colony formation rate was calculated.

**Transwell assay.** Transwell chambers (pore size,  $8\ \mu\text{m}$ ; Corning, Inc.) were used to perform the Transwell assay. To assess cell migration, 5-8F/DDP and SUNE-1/DDP cells ( $1 \times 10^5$  cells/well) in serum-free RPMI-1640 were plated into the upper chamber. Medium supplemented with 10% FBS was plated into the lower chamber. Following incubation for 24 h at  $37^{\circ}\text{C}$ , migratory cells were fixed with 4% paraformaldehyde at room temperature for 30 min and stained with 0.1% crystal violet at  $37^{\circ}\text{C}$  for 2 h. Stained cells were counted in five randomly selected fields of view using a light microscope (magnification,  $\times 200$ ). To assess cell invasion, the upper chambers were precoated with Matrigel for 30 min at  $37^{\circ}\text{C}$  and then the aforementioned protocol was performed.

**Cell Counting Kit-8 (CCK-8) assay.** Cells were seeded ( $5 \times 10^3$  cells/well) into 96-well plates. Cells were treated with different concentrations of DDP (0, 2, 4, 6, 8 or 10  $\mu\text{g/ml}$ ) for 24 h at 37°C. Subsequently, 10  $\mu\text{l}$  CCK-8 reagent (Beyotime Institute of Biotechnology) was added to each well and incubated for 2 h at 37°C with 5%  $\text{CO}_2$ . Absorbance was measured at a wavelength of 450 nm using a microplate reader.  $\text{IC}_{50}$  values were calculated as the concentration of DDP resulting in 50% inhibition of cell viability, with higher  $\text{IC}_{50}$  values suggesting higher drug resistance potential.

**Western blotting.** Total protein was extracted from cells and tissues using RIPA buffer (Beyotime Institute of Biotechnology). Protein concentrations were determined using a BCA protein assay kit (Beyotime Institute of Biotechnology). Proteins (10  $\mu\text{g}$ ) were separated via 10% SDS-PAGE and transferred to PVDF membranes (EMD Millipore). After blocking with 5% non-fat dry milk at room temperature for 2 h, the membranes were incubated overnight at 4°C with primary antibodies targeted against: USP47 (1:1,000; cat. no. ab72143; Abcam) and GAPDH (1:1,000; cat. no. ab9485; Abcam). Subsequently, the membranes were incubated with a HRP-conjugated secondary antibody (1:1,000; cat. no. ab6721; Abcam) for 1.5 h at 37°C. Protein bands were visualized using an enhanced-chemiluminescence reagent (Beyotime Institute of Biotechnology). Protein expression levels were semi-quantified using Image Lab software (version 4.1; Bio-Rad Laboratories, Inc.) with GAPDH as the loading control.

**Luciferase reporter assay.** StarBase (starbase.sysu.edu.cn/) and TargetScan (www.targetscan.org/vert\_72/) were used to predict the binding sites between miR-454 and KCNQ1OT1 or USP47. pmirGLO-KCNQ1OT1-wild-type (WT)/mutant (Mut) and pmirGLO-USP47-WT/Mut reporter plasmids were provided by Shanghai GenePharma Co., Ltd. 5-8F/DDP and SUNE-1/DDP cells ( $1 \times 10^5$ ) were co-transfected with 0.6  $\mu\text{g}$  pmirGLO-KCNQ1OT1-Wt/Mut or pmirGLO-USP47-Wt/Mut plasmid and 100 nM NC mimics or miR-454 mimics using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C. At 48 h post-transfection, luciferase activities were assessed using the dual-luciferase reporter assay system (Promega Corporation). Firefly luciferase activities were normalized to *Renilla* luciferase activities.

**RNA immunoprecipitation (RIP) assay.** RIP assays were performed to investigate whether KCNQ1OT1 and miR-454 were in the same RNA-induced silencing complex. The RIP assay was performed using the Magna RIP RNA-binding protein immunoprecipitation kit (EMD Millipore). 5-8F/DDP and SUNE-1/DDP cells were lysed using RIP lysis buffer (Beyotime Institute of Biotechnology) and incubated with 50  $\mu\text{l}$  A/G magnetic beads conjugated with argonaute RISC catalytic component 2 (Ago2) (EMD Millipore) and IgG (EMD Millipore). Subsequently, immunoprecipitated RNA was extracted. KCNQ1OT1 and miR-454 expression levels were measured via RT-qPCR.

**Statistical analysis.** Statistical analyses were performed using SPSS software (version 16.0; SPSS, Inc.). Data are presented as the mean  $\pm$  SD. Each experiment was performed in

triplicate. Comparisons among multiple groups were analyzed using one-way ANOVA followed by Tukey's post hoc test. Comparisons between two groups were analyzed using an unpaired Student's t-test. Pearson's correlation analysis was used to evaluate the correlation between the expression levels of miR-454 and KCNQ1OT1 or USP47.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**High expression of KCNQ1OT1 in DDP-resistant NPC tissues and cells.** The RT-qPCR results demonstrated that KCNQ1OT1 expression was significantly upregulated in the 29 DDP-resistant NPC tissues compared with the 21 DDP-sensitive NPC tissues (Fig. 1A). Subsequently, DDP-resistant NPC cells (5-8F/DDP and SUNE-1/DDP) were established. Cell viability and the  $\text{IC}_{50}$  values of DDP in 5-8F/DDP and SUNE-1/DDP cells were significantly higher compared with 5-8F and SUNE-1 cells, respectively (Fig. 1B and C). Furthermore, KCNQ1OT1 expression levels were significantly upregulated in 5-8F/DDP and SUNE-1/DDP cells compared with parental NPC cells (Fig. 1D). The results indicated that KCNQ1OT1 might be involved in DDP sensitivity and resistance in NPC cells.

**KCNQ1OT1 knockdown increases DDP sensitivity in NPC cells.** To explore the effect of KCNQ1OT1 knockdown on DDP resistance in NPC cells, shKCNQ1OT1 was transfected into 5-8F/DDP and SUNE-1/DDP cells to knock down KCNQ1OT1 expression (Fig. 2A). Compared with the shNC group, KCNQ1OT1 knockdown significantly decreased the  $\text{IC}_{50}$  value of DDP in 5-8F/DDP and SUNE-1/DDP cells (Fig. 2B). The CCK-8 assay results indicated that KCNQ1OT1 knockdown also significantly attenuated 5-8F/DDP and SUNE-1/DDP cell viability compared with the shNC group (Fig. 2C). In addition, the colony forming and Transwell assay results indicated that 5-8F/DDP and SUNE-1/DDP cell proliferation, migration and invasion were significantly inhibited by KCNQ1OT1 knockdown compared with the shNC group (Fig. 2D-F). Therefore, the results indicated that KCNQ1OT1 knockdown decreased DDP resistance in NPC cells.

**KCNQ1OT1 directly interacts with miR-454.** Increasing evidence has suggested that lncRNAs mediate their effects via competitively binding to miRNAs (19-22). Therefore, starBase was used to predict the miRNA targets of KCNQ1OT1. The results suggested that KCNQ1OT1 contained binding sites complementary to miR-454 (Fig. 3A). To verify the interaction, luciferase reporter and RIP assays were conducted. Compared with the corresponding NC groups, miR-454 mimics and miR-454 inhibitor significantly reduced and increased the luciferase activity of the KCNQ1OT1-WT reporter in 5-8F/DDP and SUNE-1/DDP cells, respectively, whereas the luciferase activity of the KCNQ1OT1-Mut reporter was not significantly altered (Fig. 3B). Moreover, the RIP assay results indicated that KCNQ1OT1 and miR-454 expression levels were significantly enriched in Ago2 compared with IgG (Fig. 3C). miR-454 expression was significantly higher in DDP-sensitive NPC tissues compared with DDP-resistant NPC tissues (Fig. 3D). Similarly, miR-454 expression was significantly downregulated in 5-8F/DDP




Figure 1. High expression of KCNQ1OT1 in DDP-resistant NPC tissues and cells. (A) KCNQ1OT1 expression levels in DDP-sensitive and DDP-resistant NPC tissues. Cell Counting Kit-8 assays were performed to detect cell viability and calculate the IC<sub>50</sub> values of DDP in (B) 5-8F/DDP, 5-8F, (C) SUNE-1/DDP and SUNE-1 cells. (D) KCNQ1OT1 expression levels in 5-8F/DDP, 5-8F, SUNE-1/DDP and SUNE-1 cells. Data are presented as the mean ± SD. \*P<0.05. KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; DDP, cisplatin; NPC, nasopharyngeal carcinoma; RT-qPCR, reverse transcription-quantitative PCR; Cis, cisplatin; OD, optical density.




Figure 2. KCNQ1OT1 knockdown increases nasopharyngeal carcinoma cell DDP sensitivity. (A) Transfection efficiency of shKCNQ1OT1 in 5-8F/DDP and SUNE-1/DDP cells. (B) CCK-8 assays were performed to detect cell viability and calculate the IC<sub>50</sub> values of DDP in 5-8F/DDP and SUNE-1/DDP cells transfected with shNC or shKCNQ1OT1. (C) CCK-8 assays were performed to detect the cell viability of 5-8F/DDP and SUNE-1/DDP cells transfected with shKCNQ1OT1. (D) Colony forming (magnification, x40), (E) Transwell migration and (F) Transwell invasion assays were performed to assess cell proliferation, migration and invasion in 5-8F/DDP and SUNE-1/DDP cells transfected with shNC or shKCNQ1OT1 (scale bar, 100 µm). Data are presented as the mean ± SD. \*P<0.05. KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; DDP, cisplatin; sh, short hairpin RNA; CCK-8, Cell Counting Kit-8; NC, negative control; OD, optical density.




Figure 3. KCNQ1OT1 directly interacts with miR-454. (A) Binding sites between miR-454 and KCNQ1OT1. (B) Luciferase activity of KCNQ1OT1-WT and KCNQ1OT1-Mut in 5-8F/DDP and SUNE-1/DDP cells following transfection with NC mimics, miR-454 mimics, NC inhibitor or miR-454 inhibitor. (C) RNA immunoprecipitation assays were performed to assess the interaction between KCNQ1OT1 and miR-454. (D) miR-454 expression levels in DDP-sensitive and DDP-resistant NPC tissues. (E) miR-454 expression levels in 5-8F/DDP, 5-8F, SUNE-1/DDP and SUNE-1 cells. (F) Correlation between KCNQ1OT1 expression and miR-454 expression in NPC tissues. (G) Transfection efficiency of pcDNA3.1-KCNQ1OT1 and shKCNQ1OT1. (H) miR-454 expression levels in 5-8F/DDP and SUNE-1/DDP cells transfected with pcDNA3.1, pcDNA3.1-KCNQ1OT1, shNC or shKCNQ1OT1. Data are presented as the mean  $\pm$  SD. \* $P < 0.05$ . KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; WT, wild-type; Mut, mutant; NC, negative control; DDP, cisplatin; NPC, nasopharyngeal carcinoma; sh, short hairpin RNA; Ago2, argonaute RISC catalytic component 2; Cis, cisplatin.

and SUNE-1/DDP cells compared with parental NPC cells (Fig. 3E). The expression levels of KCNQ1OT1 were negatively correlated with miR-454 expression levels in NPC tissues (Fig. 3F). To explore whether KCNQ1OT1 regulated miR-454 expression, pcDNA3.1-KCNQ1OT1 and shKCNQ1OT1 were transfected into 5-8F/DDP and SUNE-1/DDP cells to overexpress or knock down KCNQ1OT1 expression, respectively (Fig. 3G), and then miR-454 expression levels were measured. The results demonstrated that KCNQ1OT1 overexpression significantly downregulated miR-454 expression compared with the pcDNA3.1 group, whereas KCNQ1OT1 knockdown significantly increased miR-454 expression levels compared with the shNC group (Fig. 3H). Collectively, the results indicated that KCNQ1OT1 served as a molecular sponge for miR-454.

*KCNQ1OT1 modulates the sensitivity of DDP-resistant NPC cells by downregulating miR-454.* To further investigate whether KCNQ1OT1 exerted its function in the DDP resistance of NPC cells by regulating

miR-454 expression, miR-454 was overexpressed in 5-8F/DDP and SUNE-1/DDP cells by transfection with miR-454 mimics (Fig. 4A). Subsequently, 5-8F/DDP and SUNE-1/DDP cells were transfected with NC mimics, miR-454 mimics, miR-454 mimics + pcDNA3.1 or miR-454 mimics + pcDNA3.1-KCNQ1OT1. The CCK-8 assay results indicated that compared with the NC mimics group, miR-454 overexpression significantly suppressed cell viability, which was significantly reversed by co-transfection with pcDNA3.1-KCNQ1OT1 (Fig. 4B). Furthermore, the colony forming and Transwell assay results demonstrated that pcDNA3.1-KCNQ1OT1 significantly reversed miR-454 overexpression-induced inhibition of 5-8F/DDP and SUNE-1/DDP cell proliferation, migration and invasion (Fig. 4C-E). Collectively, the results indicated that KCNQ1OT1 enhanced DDP resistance in NPC cells by downregulating miR-454 expression.

*USP47 is directly targeted by miR-454.* The binding sites of miR-454 on the 3'-UTR of USP47 were predicted using






Figure 4. KCNQ1OT1 modulates the sensitivity of DDP-resistant nasopharyngeal carcinoma cells by downregulating miR-454. (A) Transfection efficiency of miR-454 mimics. (B) Cell Counting Kit-8 assays were performed to detected the cell viability of 5-8F/DDP and SUNE-1/DDP cells transfected with NC mimics, miR-454 mimics, miR-454 mimics + pcDNA3.1 or miR-454+ pcDNA3.1-KCNQ1OT1. (C) Colony forming (magnification, x40), (D) Transwell migration and (E) Transwell invasion assays were performed to assess cell proliferation, migration and invasion in 5-8F/DDP and SUNE-1/DDP cells transfected with NC mimics, miR-454 mimics, miR-454 mimics + pcDNA3.1 or miR-454+ pcDNA3.1-KCNQ1OT1 (scale bar, 100  $\mu$ m). Data are presented as the mean  $\pm$  SD. \* $P$ <0.05. KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; DDP, cisplatin; miR, microRNA; NC, negative control; OD, optical density.

TargetScan software (Fig. 5A). Compared with the corresponding NC groups, miR-454 mimics significantly inhibited the luciferase activity of USP47-WT, whereas miR-454 inhibitor significantly increased the luciferase activity of USP47-WT in 5-8F/DDP and SUNE-1/DDP cells (Fig. 5B). The RIP assay results demonstrated that miR-454 and USP47 expression levels were significantly enriched in Ago2 compared with IgG (Fig. 5C). In addition, USP47 expression was significantly upregulated in

DDP-resistant NPC tissues compared with DDP-sensitive NPC tissues (Fig. 5D). The RT-qPCR and western blotting results indicated that USP47 mRNA and protein expression levels were increased in DDP-resistant NPC cells compared with parental NPC cells (Fig. 5E and F). Pearson's correlation analysis suggested that USP47 expression was negatively correlated with miR-454 expression in NPC tissues (Fig. 5G). The aforementioned results indicated that USP47 was a target of miR-454.




Figure 5. USP47 is directly targeted by miR-454. (A) Binding sites between miR-454 and the 3'-untranslated region of USP47. (B) Luciferase activity of USP47-WT and USP47-Mut in 5-8F/DDP and SUNE-1/DDP cells following transfection with NC mimics, miR-454 mimics, NC inhibitor or miR-454 inhibitor. (C) RNA immunoprecipitation assays were performed to assess the interaction between USP47 and miR-454. (D) USP47 expression levels in DDP-resistant and DDP-sensitive NPC tissues. (E) USP47 mRNA and (F) protein expression levels in DDP-resistant NPC cells. (G) Correlation between USP47 expression and miR-454 expression in NPC tissues. Data are presented as the mean  $\pm$  SD. \* $P < 0.05$ . USP47, ubiquitin specific peptidase 47; miR, microRNA; WT, wild-type; Mut, mutant; DDP, cisplatin; NC, negative control; NPC, nasopharyngeal carcinoma; Ago2, argonaute RISC catalytic component 2.

*KCNQ1OT1 confers DDP resistance in NPC cells via upregulating USP47 expression by sponging miR-454.* Subsequently, the RT-qPCR results demonstrated that miR-454 and USP47 expression levels were significantly decreased in 5-8F/DDP and SUNE-1/DDP cells following transfection with miR-454 inhibitor or shUSP47 compared with the NC inhibitor and shNC groups, respectively, which suggested that miR-454 inhibitor and shUSP47 downregulated miR-454 and USP47 expression levels in DDP-resistant NPC cells, respectively (Fig. 6A and B). In addition, 5-8F/DDP cells were transfected with shNC, shUSP47, shUSP47 + NC inhibitor or shUSP47 + miR-454 inhibitor. The CCK-8 assay results demonstrated that USP47 knockdown significantly reduced cell viability compared with the shNC group, which was significantly reversed by co-transfection with miR-454 knockdown in 5-8F/DDP and SUNE-1/DDP cells (Fig. 6C). The colony forming and Transwell assay results demonstrated that

miR-454 knockdown significantly reversed shUSP47-induced inhibitory effects on DDP-resistant NPC cell proliferation, migration and invasion (Fig. 6D-F). Collectively, the results demonstrated that miR-454 participated in DDP resistance in NPC via USP47.

*USP47 expression is regulated by KCNQ1OT1 and miR-454.* Pearson's correlation analysis suggested that USP47 expression was positively correlated with KCNQ1OT1 expression in NPC tissues (Fig. 7A). To further determine whether KCNQ1OT1 mediated its effects via regulating the miR-454/USP47 axis, 5-8F/DDP and SUNE-1/DDP cells were transfected with shNC, shKCNQ1OT1, shKCNQ1OT1+ NC inhibitor or shKCNQ1OT1 + miR-454 inhibitor. The RT-qPCR results suggested that USP47 expression was significantly downregulated in KCNQ1OT1-knockdown DDP-resistant NPC cells compared with the shNC group, and miR-454 knockdown significantly




Figure 6. KCNQ1OT1 confers NPC cell DDP resistance via upregulating USP47 expression in NPC cells by sponging miR-454. (A) Transfection efficiency of miR-454 inhibitor. (B) USP47 expression levels in 5-8F/DDP and SUNE-1/DDP cells transfected with shNC or shUSP47. (C) Cell Counting Kit-8 assays were performed to detect the cell viability of 5-8F/DDP and SUNE-1/DDP cells transfected with shNC, shUSP47, shUSP47 + NC inhibitor or shUSP47 + miR-454 inhibitor. (D) Colony forming (magnification, x40), (E) Transwell migration and (F) Transwell invasion assays were performed to assess cell proliferation, migration and invasion in 5-8F/DDP and SUNE-1/DDP cells transfected with shNC, shUSP47, shUSP47 + NC inhibitor or shUSP47 + miR-454 inhibitor (scale bar, 100  $\mu$ m). Data are presented as the mean  $\pm$  SD. \* $P$ <0.05. KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; NPC, nasopharyngeal carcinoma; DDP, cisplatin; USP47, ubiquitin specific peptidase 47; miR, microRNA; sh, short hairpin RNA; NC, negative control.




Figure 7. USP47 expression is regulated by KCNQ1OT1 and miR-454. (A) Correlation between USP47 expression and KCNQ1OT1 expression in nasopharyngeal carcinoma tissues. (B) USP47 expression levels in 5-8F/DDP and SUNE-1/DDP cells transfected with shNC, shKCNQ1OT1, shKCNQ1OT1 + NC inhibitor or shKCNQ1OT1 + miR-454 inhibitor. Data are presented as the mean  $\pm$  SD. \* $P$ <0.05. USP47, ubiquitin specific peptidase 47; KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; miR, microRNA; DDP, cisplatin; sh, short hairpin RNA; NC, negative control.



reversed KCNQ1OT1 knockdown-mediated downregulation of USP47 expression levels (Fig. 7B). The results indicated that KCNQ1OT1 contributed to DDP resistance in NPC cells via regulating the miR-454/USP47 axis.

## Discussion

Increasing evidence has indicated that abnormal lncRNAs might lead to drug resistance in various types of cancer (23-25), including NPC (26,27). The present study demonstrated that compared with the shNC group, KCNQ1OT1 knockdown significantly suppressed cell viability and promoted DDP sensitivity in DDP-resistant NPC cells by sponging miR-454 via downregulating USP47. Moreover, the results suggested that the KCNQ1OT1/miR-454/USP47 axis participated in the regulation of DDP resistance in NPC.

KCNQ1OT1 is an imprinted antisense lncRNA located at 11p15.5 (28,29). Recent studies have suggested that KCNQ1OT1 is closely associated with the drug resistance of various tumors. For example, DDP-induced KCNQ1OT1 regulated the chemoresistance of tongue cancer via regulating the miR-124-3p/tripartite motif containing 14 axis (30). The lncRNA KCNQ1OT1/miR-34a axis increased the chemoresistance of colon cancer cells by targeting autophagy related 4B cysteine peptidase (31). Moreover, KCNQ1OT1 knockdown sensitized osteosarcoma cells to DDP and inhibited cell invasion via the potassium voltage-gated channel subfamily Q member 1/DNA methyltransferase 1 axis (32). In the present study, the functions and mechanisms underlying KCNQ1OT1-induced DDP resistance in NPC were investigated. The results indicated that KCNQ1OT1 expression was significantly increased in DDP-resistant NPC compared with DDP-sensitive NPC, and KCNQ1OT1 knockdown significantly suppressed NPC cell viability and DDP resistance compared with the shNC group.

Previous studies have revealed that lncRNAs might serve as competitive endogenous RNAs for miRNAs to alter the binding of miRNAs and miRNA target gene expression levels (33-36). The present study demonstrated that KCNQ1OT1 directly interacted with miR-454. miR-454 has been reported to serve vital roles in tumor proliferation, apoptosis and metastasis in various types of cancer. For example, miR-454 remarkably inhibited bladder cancer cell invasion and migration via targeting ZEB2 antisense RNA 1 (37). miR-454 overexpression accelerated apoptosis and suppressed proliferation of glioblastoma cells by downregulating nuclear factor of activated T cells 2 (38). Moreover, miR-454 inhibition decreased the repressive effects of HOXA11 antisense RNA knockdown on DDP-resistant non-small cell lung cancer cells (39). In the present study, compared with the NC mimics group, miR-454 overexpression significantly inhibited cell viability and promoted sensitivity to DDP in DDP-resistant NPC cells, but KCNQ1OT1 overexpression reversed the effects of miR-454 overexpression on cell viability and DDP sensitivity.

USP47 is a member of the deubiquitinating enzyme family (40). Previous studies have revealed that USP47 was abnormally expressed in multiple types of cancer (41-43). For example, USP47 overexpression accelerated ovarian cancer cell development (44), whereas USP47 knockdown inhibited gastric

cancer cell proliferation (45). USP47 facilitated osteosarcoma cell invasion and migration, and suppressed apoptosis (46). In the present study, USP47 was identified as a target of miR-454, and USP47 knockdown significantly inhibited cell viability and DDP resistance in NPC cells compared with the shNC group. Furthermore, miR-454 knockdown significantly reversed shUSP47-mediated effects in DDP-resistant NPC cells. Compared with the shNC group, KCNQ1OT1 knockdown significantly downregulated USP47 expression, and miR-454 knockdown significantly reversed shKCNQ1OT1-mediated effects on USP47 expression.

However, the present study had a number of limitations. Firstly, other mRNAs should be explored to determine the downstream regulatory mechanism underlying the KCNQ1OT1/miR-454 axis. Secondly, the present study lacked *in vivo* experiments, which should be performed in future studies to further the understanding of the mechanism underlying NPC.

In conclusion, the results of the present study suggested that KCNQ1OT1 facilitated cell viability and DDP resistance in NPC cells via regulating the miR-454/USP47 axis. Therefore, KCNQ1OT1 might serve as a potential target for overcoming DDP resistance in the chemotherapy of NPC.

## Acknowledgements

Not applicable.

## Funding

No funding was received.

## Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

## Authors' contributions

FY, ZZ and XY designed the study. FY and ZL performed the experiments. FY and ZL analysed the data and prepared the figures. FY and ZZ drafted the initial manuscript. FY and XY reviewed and revised the manuscript. All authors read and approved the final manuscript. ZZ and XY confirm the authenticity of all the raw data.

## Ethics approval and consent to participate

The present study was approved by the Ethical Committee of Zhuji Central Hospital. Written consent were obtained from all patients prior to starting the study.

## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

- Wang M, Ji YQ, Song ZB, Ma XX, Zou YY and Li XS: Knockdown of lncRNA ZFAS1 inhibits progression of nasopharyngeal carcinoma by sponging miR-135a. *Neoplasma* 66: 939-945, 2019.
- Kong YG, Cui M, Chen SM, Xu Y, Xu Y and Tao ZZ: LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. *Gene* 639: 77-84, 2018.
- Lee VH, Lam KO, Chang AT, Lam TC, Chiang CL, So TH, Choi CW and Lee AW: Management of nasopharyngeal carcinoma: Is adjuvant therapy needed? *J Oncol Pract* 14: 594-602, 2018.
- Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, Facchini G, Gargiulo P, Rossetti S, Mangili G, *et al*: Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. *Gynecol Oncol* 144: 72-76, 2017.
- Peng X, Li W and Tan G: Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thrombospondin-1 expression. *Anticancer Drugs* 21: 381-388, 2010.
- Fang Z, Zhao J, Xie W, Sun Q, Wang H and Qiao B: LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by suppressing miR-184 expression. *Cancer Med* 6: 2897-2908, 2017.
- Wang Y, Chen F, Zhao M, Yang Z, Li J, Zhang S, Zhang W, Ye L and Zhang X: The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMG2 oncogene via sequestration of the microRNA-186. *J Biol Chem* 292: 15395-15407, 2017.
- Wu X, Zhang P, Zhu H, Li S, Chen X and Shi L: Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway. *Biomed Pharmacother* 96: 1103-1108, 2017.
- Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, Chen W, Liu F, Sun W, Li XF, *et al*: Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. *Cancer Cell* 29: 653-668, 2016.
- Zhang Y, Song X, Wang X, Hu J and Jiang L: Silencing of LncRNA HULC enhances chemotherapy induced apoptosis in human gastric cancer. *J Med Biochem* 35: 137-143, 2016.
- Cao C, Zhou S and Hu J: Long noncoding RNA MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma. *Int Forum Allergy Rhinol* 10: 1012-1023, 2020.
- Liu F, Tai Y and Ma J: LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. *Cancer Biol Ther* 19: 534-542, 2018.
- Gao L, Cheng XL and Cao H: LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. *Biochimie* 152: 63-72, 2018.
- Song H, Xu Y, Shi L, Xu T, Fan R, Cao M, Xu W and Song J: LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 mRNA stability. *Biomed Pharmacother* 108: 338-346, 2018.
- Zhang Y, Zhao Y, Liu L, Su H, Dong D, Wang J, Zhang Y, Chen Q and Li C: MicroRNA-19b promotes nasopharyngeal carcinoma more sensitive to cisplatin by suppressing KRAS. *Technol Cancer Res Treat* 17: 1533033818793652, 2018.
- Zhang P, Lu X, Shi Z, Li X, Zhang Y, Zhao S and Liu H: miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells. *Gene* 710: 103-113, 2019.
- Shao Q, Zhang P, Ma Y, Lu Z, Meng J, Li H, Wang X, Chen D, Zhang M, Han Y, *et al*: MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. *Gene* 652: 48-58, 2018.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
- Zheng S, Jiang F, Ge D, Tang J, Chen H, Yang J, Yao Y, Yan J, Qiu J, Yin Z, *et al*: LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma. *Biomed Pharmacother* 112: 108695, 2019.
- Li FP, Lin DQ and Gao LY: LncRNA TUG1 promotes proliferation of vascular smooth muscle cell and atherosclerosis through regulating miRNA-21/PTEN axis. *Eur Rev Med Pharmacol Sci* 22: 7439-7447, 2018.
- Liu H, Deng H, Zhao Y, Li C and Liang Y: LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. *J Exp Clin Cancer Res* 37: 279, 2018.
- Ma J, Yan H, Zhang J, Tan Y and Gu W: Long-chain non-coding RNA (lncRNA) MT1JP suppresses biological activities of lung cancer by regulating miRNA-423-3p/Bim Axis. *Med Sci Monit* 25: 5114-5126, 2019.
- Hu M, Zhang Q, Tian XH, Wang JL, Niu YX and Li G: LncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis. *Mol Carcinog* 58: 2207-2217, 2019.
- Fu D, Lu C, Qu X, Li P, Chen K, Shan L and Zhu X: LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis. *Aging (Albany NY)* 11: 8374-8385, 2019.
- Zhuang X, Shen L, Yang L, Huang X, Lu Q, Cui Y, Zheng X, Zhao X, Zhang D, Huang R, *et al*: TGFβ1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. *Theranostics* 7: 3053-3067, 2017.
- Li H, Huang J, Yu S and Lou Z: Long non-coding RNA DLEU1 Up-regulates BIRC6 expression by competitively sponging miR-381-3p to promote cisplatin resistance in nasopharyngeal carcinoma. *Oncotargets Ther* 13: 2037-2045, 2020.
- Lin FJ, Lin XD, Xu LY and Zhu SQ: Long Noncoding RNA HOXA11-AS modulates the resistance of nasopharyngeal carcinoma cells to cisplatin via miR-454-3p/c-Met. *Mol Cells* 43: 856-869, 2020.
- Kang Y, Jia Y, Wang Q, Zhao Q, Song M, Ni R and Wang J: Long Noncoding RNA KCNQIOT1 promotes the progression of non-small cell lung cancer via regulating miR-204-5p/ATG3 Axis. *Oncotargets Ther* 12: 10787-10797, 2019.
- Lu X, Wang F, Fu M, Li Y and Wang L: [ARTICLE WITHDRAWN] Long Noncoding RNA KCNQIOT1 Accelerates the Progression of Ovarian Cancer via MicroRNA-212-3/LCN2 Axis. *Oncol Res* 28: 135-146, 2020.
- Qiao CY, Qiao TY, Jin H, Liu LL, Zheng MD and Wang ZL: LncRNA KCNQIOT1 contributes to the cisplatin resistance of tongue cancer through the KCNQIOT1/miR-124-3p/TRIM14 axis. *Eur Rev Med Pharmacol Sci* 24: 200-212, 2020.
- Li Y, Li C, Li D, Yang L, Jin J and Zhang B: lncRNA KCNQIOT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. *Oncotargets Ther* 12: 2649-2660, 2019.
- Qi X, Yu XJ, Wang XM, Song TN, Zhang J, Guo XZ, Li GJ and Shao M: Knockdown of KCNQIOT1 suppresses cell invasion and sensitizes osteosarcoma cells to CDDP by upregulating DNMT1-Mediated Kcnq1 expression. *Mol Ther Nucleic Acids* 17: 804-818, 2019.
- Wang P, Chen D, Ma H and Li Y: LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. *Oncotargets Ther* 10: 5137-5149, 2017.
- Chen J, Yu Y, Li H, Hu Q, Chen X, He Y, Xue C, Ren F, Ren Z, Li J, *et al*: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. *Mol Cancer* 18: 33, 2019.
- Liu ZZ, Tian YF, Wu H, Ouyang SY and Kuang WL: LncRNA H19 promotes glioma angiogenesis through miR-138/HIF-1α/VEGF axis. *Neoplasma* 67: 111-118, 2020.
- Fu C, Li D, Zhang X, Liu N, Chi G and Jin X: LncRNA PVT1 facilitates tumorigenesis and progression of glioma via regulation of MiR-128-3p/GREM1 Axis and BMP signaling pathway. *Neurotherapeutics* 15: 1139-1157, 2018.
- Wang S, Zhang G, Zheng W, Xue Q, Wei D, Zheng Y and Yuan J: MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targeting ZEB2. *Biosci Rep* 38: BSR20181436, 2018.
- Zuo J, Yu H, Xie P, Liu W, Wang K and Ni H: miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma. *Gene* 710: 233-239, 2019.
- Zhao X, Li X, Zhou L, Ni J, Yan W, Ma R, Wu J, Feng J and Chen P: LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. *Cancer Sci* 109: 3068-3079, 2018.
- Yu L, Dong L, Wang Y, Liu L, Long H, Li H, Li J, Yang X, Liu Z, Duan G, *et al*: Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression. *Cancer Lett* 448: 40-51, 2019.

41. Yan S, Yue Y, Wang J, Li W, Sun M, Gu C and Zeng L: LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. *Eur J Pharmacol* 858: 172464, 2019.
42. Naghavi L, Schwalbe M, Ghanem A and Naumann M: Deubiquitinylase USP47 promotes RelA phosphorylation and survival in gastric cancer cells. *Biomedicines* 6: 62, 2018.
43. Cho J, Park J, Shin SC, Jang M, Kim JH and Kim EE and Song EJ: USP47 promotes tumorigenesis by negative regulation of p53 through deubiquitinating ribosomal protein S2. *Cancers (Basel)* 12: 1137, 2020.
44. Hu L, Kolibaba H, Zhang S, Cao M, Niu H, Mei H, Hao Y, Xu Y and Yin Q: MicroRNA-204-5p inhibits ovarian cancer cell proliferation by down-regulating USP47. *Cell Transplant* 28 (1 suppl): S51-S58, 2019.
45. Zhang B, Yin Y, Hu Y, Zhang J, Bian Z, Song M, Hua D and Huang Z: MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. *Med Oncol* 32: 331, 2015.
46. Zhang S, Ding L, Gao F and Fan H: Long non-coding RNA DSCAM-AS1 upregulates *USP47* expression through sponging miR-101-3p to accelerate osteosarcoma progression. *Biochem Cell Biol* 98: 600-611, 2020.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.